A trial of VIS649, an monoclonal antibody, for the treatment of IgA nephropathy.

Trial Profile

A trial of VIS649, an monoclonal antibody, for the treatment of IgA nephropathy.

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs VIS 649 (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions
  • Sponsors Visterra
  • Most Recent Events

    • 17 Nov 2017 Status changed from not stated to planning.
    • 16 Nov 2017 New trial record
    • 18 Oct 2017 According to Visterra media release, company plans to initiate the trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top